Acquisition by Banque Soria Ester of 140 shares of Zoetis subject to Rule 16b-3
| ZTS Stock | USD 167.24 2.26 1.37% |
Slightly above 51% of Zoetis' private investors are presently thinking to get in. The analysis of overall sentiment of trading Zoetis Inc stock suggests that some investors are interested at this time. Zoetis' investing sentiment can be driven by a variety of factors including economic data, Zoetis' earnings reports, geopolitical events, and overall market trends.
Zoetis |
Filed transaction by Zoetis Inc Officer: Executive Vice President. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at accesswire.com
 |
Zoetis Fundamental Analysis
We analyze Zoetis' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Zoetis using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Zoetis based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash And Equivalents
Cash And Equivalents Comparative Analysis
Zoetis is currently under evaluation in cash and equivalents category among its peers. Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Zoetis Inc Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Zoetis stock to make a market-neutral strategy. Peer analysis of Zoetis could also be used in its relative valuation, which is a method of valuing Zoetis by comparing valuation metrics with similar companies.
Peers
Zoetis Related Equities
| EBS | Emergent Biosolutions | 5.95 | ||||
| HLN | Haleon Plc | 3.98 | ||||
| ELAN | Elanco Animal | 2.29 | ||||
| NBIX | Neurocrine Biosciences | 1.03 | ||||
| TEVA | Teva Pharma | 0.86 | ||||
| TAK | Takeda Pharmaceutical | 0.49 | ||||
| ITCI | Intracellular | 0.04 | ||||
| ALVO | Alvotech | 0.87 | ||||
| ASRT | Assertio Therapeutics | 2.50 | ||||
| BHC | Bausch Health | 2.75 | ||||
| VTRS | Viatris | 3.15 | ||||
| AMPH | Amphastar | 9.72 |
Additional Tools for Zoetis Stock Analysis
When running Zoetis' price analysis, check to measure Zoetis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zoetis is operating at the current time. Most of Zoetis' value examination focuses on studying past and present price action to predict the probability of Zoetis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zoetis' price. Additionally, you may evaluate how the addition of Zoetis to your portfolios can decrease your overall portfolio volatility.